Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. This study assesses the clinical and analytical performance of the Elecsys® PIVKA-II immunoassay in diagnosing HCC and evaluate PIVKA-II’s technical performance.
Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein HG, Hegel JK, Sharma A, Madin K, Rolny V, Lisy MR, Piratvisuth T…
Cancer Type: Liver
Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
Performance Evaluation of the Elecsys GAAD Assay for the Detection of Hepatocellular Carcinoma Across Different Disease Stages and Etiologies
The Elecsys® GAAD algorithm combines quantitative measurements of Elecsys PIVKA-II assay and Elecsys AFP assay, plus age and gender to generate a semi-quantitative result. This study aimed to assess the clinical performance of the Elecsys GAAD algorithm to differentiate HCC and benign chronic liver disease, according to disease stage and etiology.
Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein HG, Hegel JK, Kroeniger K, Madin K, Sharma A, Piratvisuth T…
Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study
This study systematically evaluates biomarkers mentioned in international guidelines and peer-reviewed literature for HCC surveillance and diagnosis, in order to identify combinations of biomarkers that display high sensitivity and specificity for early stage HCC detection.
Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HLY…
Elecsys PIVKA-II and Elecsys AFP assays demonstrate good clinical performance for hepatocellular carcinoma (HCC) diagnosis across different disease stages and aetiologies
This study evaluates the clinical performance of the new Elecsys PIVKA-II immunoassay and the previously launched Elecsys AFP assay (Roche Diagnostics) to aid in the diagnosis of HCC, according to disease stage and etiology.
Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Weinmann A, Eiblmaier A, Klein HG, Hegel JK, Morgenstern D, Madin K, Rolny V, Lisy MR, Piratvisuth T…
Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify Elecsys PIVKA-II and conventional Lumipulse PIVKA-II from the serum samples of patients with unresectable HCC undergoing systemic therapy.
Kaneko S, Kurosaki M, Tsuchiya K, Yasui Y, Hayakawa Y, Inada K, Tanaka Y, Ishido S, Kirino S, Yamashita K, Nobusawa T, Matsumoto H, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Takahashi Y, Nakanishi H, Izumi N…
APACMed White Paper – Strengthening Healthcare Systems Through the Critical Role of Diagnostics
Diagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite its important role, diagnostics have been historically under prioritized. Read how APACMed seeks to improve the value recognition of diagnostic solutions.
Hardesty CL, Sarno R, Pelou C, Teng G, Aslam B, Bourcet A, Nair AKR, Wang J, Lina Y, Wearne D, Panth A, Rua C, Ho R, Kumar SA, Freitas E, Charafi N, Tan V, Chen JS, Veigas V, Teo P…